This is table 1 of the Magellan Longevity Open Evidence Dataset, rendered so you can read it without downloading anything. Sorted strongest evidence first, then by how many peer-reviewed citations sit behind the product. The caveat column is the part most evidence tables leave out: it is where the grade is qualified, contradicted or explicitly walked back.
Machine-readable copies: CSV · JSON · JSONL. Field definitions: data dictionary. Grading rubric: on the dataset page or in the store.
| Product | Grade | Category | Pathway | Cites | Studied dose | Caveat (what qualifies the grade) |
|---|---|---|---|---|---|---|
| Betaine (TMG) | Strong evidence | Nutraceuticals & Cellular Energizers | Epigenetic / TCA | 23 | 1.5–6 g/day in trials | Reliably lowers homocysteine (dose-dependent, meta-analyzed) and is FDA-approved for homocystinuria, but homocysteine reduction has never been shown to prevent cardiovascular events. At 4 g/day or more it modestly raises total cholesterol, and NASH and body-composition trials were null. |
| Creatine Monohydrate | Strong evidence | Nutraceuticals & Cellular Energizers | Muscle & Bone | 23 | 3–5 g/day (creatine monohydrate); an optional ~20 g/day loading week works faster but isn’t required | One of the most studied supplements there is: dozens of randomized trials and meta-analyses show reliable gains in strength, power and lean muscle alongside resistance training, and it is well tolerated in healthy people. The strong evidence is for muscle and exercise performance; cognitive, bone and healthy-aging… |
| Bright Light Therapy Lamp | Strong evidence | Air, Water & Sleep Systems | Circadian & Stress | 21 | ~10,000 lux white light for ~30 min each morning | Bright light is a first-line treatment for seasonal depression, and meta-analyses show it roughly doubles remission and response rates as an adjunct in nonseasonal depression; sleep benefits are smaller and the studies more heterogeneous. Effectiveness depends on correct use (morning timing, sufficient intensity),… |
| Hand Grip Dynamometer Pro | Strong evidence | Air, Water & Sleep Systems | Muscle & Bone | 21 | — | Lower grip strength is one of the most robust mortality risk markers in epidemiology — consistent across millions of participants and stronger than systolic blood pressure in the PURE cohort — but it is a marker, not a treatment: no trial shows that raising grip strength itself lowers mortality. Its value is tracking… |
| Lutein and Zeaxanthin | Strong evidence | Nutraceuticals & Cellular Energizers | Brain & Cognition | 21 | 10 mg lutein + 2 mg zeaxanthin daily (the AREDS2 formulation) | Proven to slow progression of age-related macular degeneration in people who already have intermediate or late disease — it does not prevent AMD in healthy eyes, and cognitive benefits are unproven (null in AREDS2's older participants). Unlike the beta-carotene it replaced, it is safe for former smokers. |
| Azelaic Acid Gel | Strong evidence | Skin & Topical Longevity | Gut–Immune Axis | 20 | 15-20% topical gel/cream (prescription strengths used in most trials) | Strong dermatology evidence for rosacea, acne and melasma at prescription 15-20% strengths, built on decades of RCTs and GRADE-assessed reviews. Benefit at over-the-counter ~10% cosmetic doses is plausible but less directly proven. Mild, transient stinging is the most common side effect; a skin-health product, not a… |
| Validated Home BP Monitor | Strong evidence | Air, Water & Sleep Systems | Cardiovascular & Vascular | 20 | — | Trials and an individual-patient meta-analysis show home monitoring lowers blood pressure only when paired with clinician-guided titration or similar support (about 3.5-6 mmHg systolic at 12 months); the device alone does little. Accuracy depends on buying an independently validated monitor and using the right cuff… |
| 24h Ambulatory BP Monitor | Strong evidence | Air, Water & Sleep Systems | Cardiovascular & Vascular | 19 | — | Large international cohorts and a 2025 patient-level meta-analysis consistently show 24-hour and nighttime ambulatory readings predict death and cardiovascular events better than office measurements, and US guidelines recommend confirming hypertension out-of-office. No randomized trial has shown that ABPM-guided… |
| Balance and Strength Trainer | Strong evidence | Recovery, Sauna & Light Therapy | Muscle & Bone | 19 | Balance-challenging exercise ~3+ hours/week; strength training ~30–60 min/week | Fall prevention through balance plus strength exercise is among the highest-certainty findings in geriatric exercise science (Cochrane high-certainty; USPSTF Grade B recommendation). The evidence supports the training itself, not any specific device — benefit depends on regular, progressive use, and frail users… |
| Daily Mineral SPF Sunscreen | Strong evidence | Skin & Topical Longevity | Connective Tissue | 19 | Daily broad-spectrum SPF 15 or higher, applied in adequate amounts | One of the few anti-aging interventions with randomized-trial proof: 24% less visible skin aging over 4.5 years, plus fewer melanomas at 10-year follow-up. Benefits require consistent daily use; evidence for preventing basal and squamous cell carcinoma is less certain. Mineral zinc oxide and titanium dioxide are the… |
| Voltaren Arthritis Pain Gel (Diclofenac 1%) | Strong evidence | Topical Pain Relief | NSAID / Prostaglandin | 17 | 1% gel (~2–4 g) over the joint up to 4×/day; relief builds over ~7 days | The best-evidenced OTC pain topical — Cochrane and meta-analysis support for hand and knee osteoarthritis, with low systemic absorption. Relief is symptomatic and modest (about 1 in 10 extra users gets at least halved pain over 6–12 weeks), and it is still an NSAID: don’t combine with oral NSAIDs without advice, and… |
| DaVinci Labs NAD+ ACTIVATE | Moderate evidence | Nutraceuticals & Cellular Energizers | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one dose-finding trial reporting benefits… | Oral NMN reliably raises blood NAD⁺ and has been well tolerated in trials up to about 900–1,250 mg/day. Functional benefits so far are modest and population-specific (muscle insulin sensitivity in prediabetic women, aerobic capacity, walking speed, sleep quality), several meta-analyses are null for glucose, lipids… |
| Double Wood NMN Capsules | Moderate evidence | Nutraceuticals & Cellular Energizers | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one dose-finding trial reporting benefits… | Oral NMN reliably raises blood NAD⁺ and has been well tolerated in trials up to about 900–1,250 mg/day. Functional benefits so far are modest and population-specific (muscle insulin sensitivity in prediabetic women, aerobic capacity, walking speed, sleep quality), several meta-analyses are null for glucose, lipids… |
| NMN Complex 1000 mg (Micro Ingredients) | Moderate evidence | Nutraceuticals & Cellular Energizers | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one dose-finding trial reporting benefits… | Oral NMN reliably raises blood NAD⁺ and has been well tolerated in trials up to about 900–1,250 mg/day. Functional benefits so far are modest and population-specific (muscle insulin sensitivity in prediabetic women, aerobic capacity, walking speed, sleep quality), several meta-analyses are null for glucose, lipids… |
| NOVOS Boost NMN | Moderate evidence | Nutraceuticals & Cellular Energizers | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one dose-finding trial reporting benefits… | Oral NMN reliably raises blood NAD⁺ and has been well tolerated in trials up to about 900–1,250 mg/day. Functional benefits so far are modest and population-specific (muscle insulin sensitivity in prediabetic women, aerobic capacity, walking speed, sleep quality), several meta-analyses are null for glucose, lipids… |
| Nutricost NMN Capsules 500mg | Moderate evidence | Nutraceuticals & Cellular Energizers | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one dose-finding trial reporting benefits… | Oral NMN reliably raises blood NAD⁺ and has been well tolerated in trials up to about 900–1,250 mg/day. Functional benefits so far are modest and population-specific (muscle insulin sensitivity in prediabetic women, aerobic capacity, walking speed, sleep quality), several meta-analyses are null for glucose, lipids… |
| Purovitalis Liposomal β-NMN | Moderate evidence | Nutraceuticals & Cellular Energizers | NAD⁺ / Sirtuin Axis | 34 | Human RCTs used 250–1,200 mg/day orally; well-tolerated up to ~900 mg/day, with one dose-finding trial reporting benefits… | Oral NMN reliably raises blood NAD⁺ and has been well tolerated in trials up to about 900–1,250 mg/day. Functional benefits so far are modest and population-specific (muscle insulin sensitivity in prediabetic women, aerobic capacity, walking speed, sleep quality), several meta-analyses are null for glucose, lipids… |
| Ubiquinol (Reduced CoQ10) | Moderate evidence | Nutraceuticals & Cellular Energizers | Mitochondrial Energy | 27 | 100–400 mg/day (1,500 mg/day used in a multiple-system-atrophy trial) | The strongest signal is adjunctive therapy in chronic heart failure (the Q-SYMBIO trial plus a 33-trial meta-analysis), but a Cochrane review rates that evidence low certainty, and most large trials used ubiquinone rather than ubiquinol — ubiquinol's proven advantage is mainly absorption. Benefit is clearest where… |
| Acetyl-L-Carnitine (ALCAR) | Moderate evidence | Nutraceuticals & Cellular Energizers | Brain & Cognition | 26 | 1.5–3 g/day in trials | Two meta-analyses (2018 and 2026) converge on a real antidepressant effect comparable to standard drugs but with fewer side effects, plus small cognitive benefits in mild cognitive impairment and early Alzheimer's and less fatigue in the very old. Depression trials are highly heterogeneous and mostly older, and a… |
| Purovitalis Liposomal Trans-Resveratrol | Moderate evidence | Nutraceuticals & Cellular Energizers | NAD⁺ / Sirtuin Axis | 26 | Human trials span ~150 mg/day to 2 g/day; ~500 mg/day raised SIRT1 activity. Evidence suggests a U-shaped curve, with ~1 g/day… | Meta-analyses of randomized trials show small improvements in endothelial function and C-reactive protein, and one 24-month trial found cognitive and cerebrovascular benefits in postmenopausal women — from a single research group, awaiting replication. No trial shows effects on cardiovascular events, dementia or… |
| Glucosamine Chondroitin MSM (with OptiMSM) | Moderate evidence | Nutraceuticals & Cellular Energizers | Connective Tissue | 25 | The GAIT (Clegg 2006) and MOVES trials used glucosamine HCl 500 mg three times daily (1,500 mg/day) plus chondroitin sulfate 400… | Moderate evidence for knee-osteoarthritis symptom relief, strongest for pharmaceutical-grade products and moderate-to-severe pain; small trials suggest MSM adds benefit. Major guidelines disagree (OARSI and ACR advise against, ESCEO recommends prescription-grade). Mortality signals are observational and likely… |
| Personal PM2.5 Air Monitor | Moderate evidence | Air, Water & Sleep Systems | Environmental Exposure | 25 | — | The exposure it measures is unambiguous: long-term PM2.5 is one of the most replicated environmental causes of cardiovascular death, and consumer optical sensors are validated as reliable trend instruments. One trial showed monitoring with feedback cut indoor PM2.5 by a median of about 19%, but direct evidence that… |
| Pomegranate Ellagitannin Extract | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 25 | — | Human trials and meta-analyses support small blood-pressure reductions (a few mmHg) and one year-long trial suggests memory preservation, but at least one systematic review calls the blood-pressure evidence weak. The headline mitophagy benefits were shown mainly with purified urolithin A, not pomegranate extract, and… |
| Pycnogenol Pine Bark Extract | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 25 | 100–200 mg/day | Trials show small blood-pressure reductions and improved endothelial function and knee-osteoarthritis symptoms, but a Cochrane review rated nearly all pine-bark evidence very low certainty, and much of the positive literature comes from one manufacturer-funded group. No lifespan or hard-outcome data. |
| Quercetin Capsules | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 25 | ≥500 mg/day (blood-pressure effects appear mainly at 500 mg/day and above) | Meta-analyses show a small (~2–3 mmHg) blood-pressure reduction, mostly in people with hypertension; lipids and glucose show no meaningful effect, and oral bioavailability is poor. The headline 'senolytic' claims come from the dasatinib+quercetin drug combination in early trials — the biggest 2024 trial was negative… |
| Beetroot / Dietary Nitrate | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 24 | Trials use ~70–250 mL beetroot juice or concentrate delivering roughly 4–13 mmol (about 250–800 mg) nitrate per day; a typical… | Concordant meta-analyses and a pivotal RCT in hypertensives show roughly 5-8 mmHg systolic BP reductions and improved vascular function, plus modest exercise-performance gains. Most trials are small and short, diastolic effects are inconsistent, individual responses vary, and long-term outcomes (stroke, heart attack)… |
| Carnosine | Moderate evidence | Nutraceuticals & Cellular Energizers | AMPK / Metabolic | 24 | 1–2 g/day | Small, short RCTs and meta-analyses show modest glycemic improvements and a small delayed-recall benefit limited to specific memory domains. No long-term, aging, or lifespan outcomes have been tested, and several measured outcomes were null. |
| D-Glucosamine Sulfate | Moderate evidence | Nutraceuticals & Cellular Energizers | AMPK / Metabolic | 24 | Pivotal osteoarthritis trials used 1,500 mg/day of glucosamine sulfate, given once daily in the structure-modifying trials… | Decades of trials are genuinely mixed: one 3-year RCT showed slowed knee joint-space narrowing, but the NIH GAIT trial and a 2018 JAMA meta-analysis found little to no pain benefit over placebo. The UK Biobank mortality association (HR ~0.85) is observational and has drawn published selection/healthy-user-bias… |
| High-Bioavailability Curcumin | Moderate evidence | Recovery, Sauna & Light Therapy | Gut–Immune Axis | 24 | — | Strongest support is for osteoarthritis symptoms, with modest effects on inflammatory markers, lipids, and depressive symptoms; effect sizes are small and trials are short and heterogeneous in formulation. High-bioavailability products - especially piperine-boosted ones - have been linked to a growing case series of… |
| Omega-3 EPA/DHA Fish Oil | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 24 | Typical studied range 0.5-4 g/day EPA+DHA; triglyceride and blood-pressure effects are dose-dependent, clearest around 2-3… | Standard over-the-counter doses did not prevent cardiovascular events or cancer in large trials (VITAL, STRENGTH) and meta-analyses, though triglyceride lowering is real. Doses above 1 g/day carry a genuine atrial-fibrillation signal - about 13% higher incident risk in a large cohort of healthy users. |
| Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield) | Moderate evidence | Nutraceuticals & Cellular Energizers | Muscle & Bone | 24 | Triple Strength provides about 1,500 mg/day glucosamine HCl plus a chondroitin/MSM complex and 100 mg/day 5-LOXIN Boswellia… | Genuinely mixed: the NIH GAIT trial was negative overall while the MOVES trial found the combination comparable to celecoxib, and recent meta-analyses are modestly favorable. The mortality and cardiovascular associations are observational with a published selection-bias critique — not a proven longevity benefit.… |
| Probiotic Multi-Strain (50B CFU) | Moderate evidence | Nutraceuticals & Cellular Energizers | Gut–Immune Axis | 24 | Human trials commonly use about 1–50 billion CFU/day (often 10^9–10^10), with many multi-strain products at 10–25 billion CFU;… | Evidence is indication-specific: moderate-certainty Cochrane support for preventing antibiotic-associated and C. difficile diarrhea and for reducing respiratory infections, but IBS and general wellness benefits are low-certainty and strain-specific. Multi-strain, high-CFU blends are not proven better than single… |
| Saffron Extract | Moderate evidence | Nutraceuticals & Cellular Energizers | Circadian & Stress | 24 | 20–30 mg/day standardized extract (sleep studies used ~14–28 mg/day) | Meta-analyses of small RCTs show saffron beats placebo for mild-to-moderate depression and performs comparably to SSRIs with fewer side effects; sleep benefits are modest and some trials are null. Trials are short (4–12 weeks), often small and single-center, large independent replications are lacking, and it is not a… |
| Alpha-Lipoic Acid (ALA) | Moderate evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 23 | 300–600 mg/day typical (600 mg/day optimal for neuropathy symptoms); up to 1,800 mg/day used in trials | The strongest evidence is symptom relief in diabetic neuropathy plus modest glycemic, lipid, and inflammatory-marker improvements, mostly from small heterogeneous trials. The 4-year NATHAN 1 trial found no slowing of neuropathy progression, and European regulators flag a rare insulin autoimmune syndrome (autoimmune… |
| DaVinci Labs Phyto Benefits | Moderate evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 23 | As a generic blend, dosing varies by formula; studied single polyphenols differ widely (e.g. resveratrol 150–500 mg/day, EGCG… | Large cohorts link higher and more varied flavonoid intake to lower mortality, and a 281-trial meta-analysis found modest improvements in blood pressure, lipids, and glucose markers. But much of the evidence is observational (healthy-eater confounding), supplement trials use heterogeneous single compounds, and this… |
| Electrical Muscle Stimulation Unit | Moderate evidence | Recovery, Sauna & Light Therapy | Muscle & Bone | 23 | — | Trials and meta-analyses show NMES or whole-body EMS can preserve or build muscle and strength in older adults and rehab patients, mainly as an adjunct to, not a replacement for, voluntary exercise. Effects on fat loss and pain are small or absent, evidence in healthy users is limited, and effortless-abs marketing… |
| PQQ (Pyrroloquinoline Quinone) | Moderate evidence | Nutraceuticals & Cellular Energizers | Mitochondrial Energy | 23 | ~20 mg/day in trials (up to 12 weeks) | Several small, short randomized trials (roughly 30–60 people, up to 12 weeks) report better memory, attention and cerebral oxygenation at about 20 mg/day, with good tolerability. But the trials are largely Japanese and manufacturer-linked, the mitochondrial-biogenesis mechanism is shown mainly in cells and animals,… |
| Zinc Picolinate | Moderate evidence | Nutraceuticals & Cellular Energizers | Gut–Immune Axis | 23 | Cold trials used lozenges providing >75 mg/day elemental zinc; chronic daily intake should stay at or below the 40 mg adult… | Meta-analyses support zinc lozenges shortening colds by about a third, but a 2024 Cochrane update rated the evidence low-certainty. Otherwise strong trial evidence exists only for the AREDS eye formulation; immune or longevity benefits in zinc-replete adults are weakly supported, and no trials show the picolinate… |
| AllerAir Deep-Bed Carbon Purifier | Moderate evidence | Air, Water & Sleep Systems | Environmental Exposure | 22 | Run it continuously in the room you actually sleep in, sized to that room. A purifier only cleans the air in the space it… | The randomized evidence supports particle filtration, not this particular machine. Pooled across 17 sham-controlled trials, portable air cleaners lowered systolic blood pressure by about 2.3 mmHg, and a 2025 crossover trial in 154 adults living near highways found a 3.0 mmHg systolic benefit that appeared only in… |
| Aspercreme 4% Lidocaine Pain Relief Cream | Moderate evidence | Topical Pain Relief | Local Anesthetic | 22 | 4% OTC cream/patch to a small area up to 3–4×/day (the 5% patch is prescription) | Best for small, well-localised pain — the strongest evidence is the 5% patch for shingles nerve pain, though one trial found an OTC-strength patch comparable. Cochrane notes high-quality RCTs are limited, and relief is purely symptomatic. Don’t exceed the labelled area or frequency, and avoid unregulated… |
| Astaxanthin Softgels | Moderate evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 22 | 4–12 mg/day in most human trials. | Human trials most consistently show lower oxidative-stress markers and modestly better skin moisture and elasticity; metabolic, cognitive, and performance effects are weak and inconsistent. Trials are small and short, and no long-term clinical-endpoint data exist. |
| Hesperidin Citrus Flavonoid | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 22 | ~500 mg/day isolated, or via hesperidin-enriched juice | Meta-analyses converge on small improvements in lipids and inflammatory markers, with reproducible short-term endothelial benefits; blood-pressure effects are inconsistent and one 2019 meta-analysis was entirely null. No trial has tested clinical event reduction. |
| Spermidine (Wheat-Germ Extract) | Moderate evidence | Nutraceuticals & Cellular Energizers | Autophagy & Proteostasis | 22 | Cognition trials in older adults used modest, food-level doses of wheat-germ extract: 0.9 mg/day for 12 months (SmartAge) and… | The preclinical case is unusually strong and several large prospective cohorts link higher dietary spermidine intake to lower mortality — but that is observational and confounded by diet quality. The most rigorous human trial to date (12-month SmartAge) found no cognitive or biomarker benefit at the 0.9 mg/day dose… |
| Beta-Alanine | Moderate evidence | Nutraceuticals & Cellular Energizers | Muscle & Bone | 21 | 3.2-6.4 g/day for at least 2-4 weeks | Strong meta-analytic support for a small improvement in high-intensity exercise capacity (efforts of about 0.5-10 minutes); in older adults it raises muscle carnosine and may help exercise capacity, but strength, daily function, cognition and disease outcomes are unproven. Safety is clean apart from harmless… |
| Cocoa Flavanol Extract | Moderate evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 21 | 500 mg cocoa flavanols/day (the COSMOS trial dose; vascular effects plateau near ~710 mg/day) | One of the few supplements tested in a 21,000-person outcomes trial: the primary cardiovascular composite narrowly missed significance, but cardiovascular death fell 27% and meta-analyses confirm small blood-pressure and endothelial-function benefits. Global cognition and type-2-diabetes prevention were null in large… |
| Glycolic Acid AHA Serum | Moderate evidence | Skin & Topical Longevity | Connective Tissue | 21 | Leave-on serums and creams typically 4-10% glycolic acid; professional peels of 20-70% are a separate, higher-risk class | A vehicle-controlled trial and human biopsy data show real but modest, cumulative improvement in photoaging signs. Irritation and increased photosensitivity are the main trade-offs, and unsupervised high-strength peels can cause chemical burns. Benefits are cosmetic; not proven to affect longevity. |
| Grape Seed Extract | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 21 | 150–600 mg/day in trials | Meta-analyses show modest blood-pressure reductions (~2–6 mmHg systolic), largest in younger or metabolically impaired people; effects on lipids and glycemia are small and inconsistent. New fatty-liver benefits rest on two small single-country trials, one trial found no cognitive benefit, and no hard cardiovascular… |
| Inulin Prebiotic Fiber | Moderate evidence | Nutraceuticals & Cellular Energizers | Gut–Immune Axis | 21 | Human trials show prebiotic and metabolic effects at roughly 4–16 g/day, with many gut and cardiometabolic studies using about… | One of the best-studied prebiotic fibers: reliable for constipation relief, with small (~1 kg) average weight effects and small LDL/triglyceride reductions whose certainty is rated low to very low. Commonly causes gas and bloating at higher doses; not a proven longevity intervention. |
| L-Methylfolate (5-MTHF) | Moderate evidence | Nutraceuticals & Cellular Energizers | Epigenetic / TCA | 21 | 15 mg/day as antidepressant adjunct (7.5 mg was ineffective) | It reliably raises folate status and lowers homocysteine, and randomized trials plus a 2022 meta-analysis show a modest adjunctive benefit in SSRI-resistant depression at 15 mg/day with placebo-like tolerability, likely concentrated in inflammatory or metabolic subgroups. But homocysteine lowering has not translated… |
| MSM (Methylsulfonylmethane) | Moderate evidence | Nutraceuticals & Cellular Energizers | Sulfur & Cellular Support | 21 | 2-6 g/day (typical studied range) | Small randomized trials show statistically significant but clinically mild improvements in knee pain and function over 8-12 weeks, with some null results. There is no evidence of disease modification or anti-aging benefit, and effects look smaller and slower than NSAIDs. Safety is excellent (GRAS) at typical doses. |
| Green Tea EGCG Extract | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 20 | Beverage-level intake (≥2 cups/day in cohorts); keep supplemental EGCG below ~800 mg/day, the regulatory safety threshold | Cohorts link habitual green tea drinking to lower mortality and RCTs show small real effects on weight (~1 kg), blood pressure, and lipids, but effects are often not clinically meaningful. High-dose concentrated extracts carry a documented, idiosyncratic liver-injury risk, so beverage-level intake has the best… |
| Indoor CO2 Air-Quality Monitor | Moderate evidence | Air, Water & Sleep Systems | Environmental Exposure | 20 | — | Higher ventilation and lower CO2 reliably track with better cognition and sleep, and CO2 is the accepted real-time ventilation gauge. Whether CO2 itself, versus the pollutants it tracks, impairs thinking at typical indoor levels is still contested, and a monitor only helps if occupants act on its readings. |
| L-Carnitine | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 20 | ~2 g/day; analyses show no clear added benefit above ~3 g/day | The strongest human data are clinical — post-heart-attack secondary prevention, deficiency states, and frail centenarians — not healthy-longevity supplementation; weight effects are real but small (~1 kg). Chronic oral L-carnitine raises TMAO via gut bacteria, and whether moderate elevations are causal or merely risk… |
| Urolithin A (Mitopure) | Moderate evidence | Nutraceuticals & Cellular Energizers | Muscle & Bone | 20 | 1,000 mg/day in most trials (500–1,000 mg/day studied) | Several small, well-controlled randomized trials show improved muscle endurance and strength, lower inflammatory markers, and younger-looking immune-cell profiles, with an excellent safety record. But nearly all are short (4 months or less) and manufacturer-funded, some missed their primary endpoints, and there is no… |
| Vitamin K2 (MK-7) | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 20 | 180 µg/day MK-7 in the main 3-year arterial-stiffness trial. | MK-7 reliably improves vitamin K-status markers, and one 3-year RCT found modestly better arterial stiffness in postmenopausal women; but the large hard-endpoint trials on aortic-valve calcification and bone density were negative. Mortality benefits are observational only. |
| Whole-Body Vibration Plate | Moderate evidence | Recovery, Sauna & Light Therapy | Muscle & Bone | 20 | ~20-50 Hz vibration frequency (typical range studied in trials) | Meta-analyses in older adults show real gains in leg strength, balance and function like sit-to-stand, but many trials are small and low quality. Bone-density benefits are small and site-limited — a 2025 analysis found benefit only at the total femur, not the spine or femoral neck. Weight-loss and 'lymphatic… |
| Broccoli Sprout Sulforaphane | Moderate evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 19 | — | Randomized trials show real biomarker effects — enhanced carcinogen detoxification and a modest glucose-lowering signal in prediabetes — but these are surrogate markers, not proven disease-outcome reductions. Actual sulforaphane delivery varies widely between supplements unless active myrosinase is retained. Mild… |
| Magnesium Glycinate | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 19 | 250–500 mg elemental magnesium/day (sleep trials used 250 mg as bisglycinate or 500 mg; BP analyses center near ~370 mg/day) | Effect sizes are small — about 2 mmHg for blood pressure and a modest improvement in insomnia scores — and benefits look greatest in people with low baseline magnesium intake. Most evidence comes from other salt forms (oxide, citrate), so glycinate-specific superiority claims outrun the data. |
| Niacinamide (Vitamin B3) Serum | Moderate evidence | Skin & Topical Longevity | Connective Tissue | 19 | Topical 2-5%; most positive trials used 4-5% over 8-12 weeks. | Small, mostly industry-linked split-face trials show modest improvements in photoaging appearance and barrier function. The skin-cancer chemoprevention data are for ORAL nicotinamide, not a topical serum - and the randomized-trial benefit waned after stopping. |
| Olive Leaf Extract (Oleuropein) | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 19 | — | Small, short randomized trials and a 2024 meta-analysis show modest blood-pressure (~3–4 mmHg), lipid, and insulin-sensitivity improvements, but samples are small, durations short (4–12 weeks), extracts variably standardized, and no long-term outcome trials exist. An adjunct, not a substitute for antihypertensive… |
| Percussive Massage Gun | Moderate evidence | Recovery, Sauna & Light Therapy | Muscle & Bone | 19 | Most trials use about 5 minutes of treatment per muscle group. | Controlled trials support short-term gains in flexibility and reduced soreness and stiffness, with emerging data in rehab populations. It does not improve — and may transiently reduce — strength or explosive performance when used right before activity. Studies are small, short, and mostly in young athletic adults,… |
| Retinaldehyde Night Serum | Moderate evidence | Skin & Topical Longevity | Connective Tissue | 19 | 0.05–0.1% topical, applied nightly | Several small RCTs (n = 23–40, 8–12 weeks) show objective, instrument-measured improvements in wrinkles, texture and pigmentation, with less irritation than prescription tretinoin — one cream matched a series of glycolic-acid peels. Trials are short, small and often industry-linked, and they measure appearance, not… |
| Self-Myofascial Foam Roller | Moderate evidence | Recovery, Sauna & Light Therapy | Muscle & Bone | 19 | — | Meta-analyses show small, real gains in flexibility and less muscle soreness 24-48 h after hard exercise; effects on strength and performance are trivial, and it works no better than other warm-ups. 'Fascial release', detox and anti-aging claims have no human evidence. |
| Taurine | Moderate evidence | Nutraceuticals & Cellular Energizers | Muscle & Bone | 19 | 0.5–6 g/day (typical studied range) | Meta-analyses of randomized trials show modest improvements in blood pressure, glucose, triglycerides, cardiac function, and endurance performance, with a good safety record. Anti-aging claims rest on animal lifespan data: no human trial shows slowed aging, and 2025 analyses found human taurine levels do not reliably… |
| Vitamin C (L-Ascorbic) Serum | Moderate evidence | Skin & Topical Longevity | Connective Tissue | 19 | 5–20% L-ascorbic acid, pH below 3.5, applied consistently for weeks to months | A small set of RCTs and systematic reviews supports modest improvements in photoaging signs and pigmentation with consistent long-term use. Results depend heavily on formulation stability, and the benefits are cosmetic and dermatologic — not a systemic or longevity effect. |
| Bakuchiol Retinol-Alternative Cream | Moderate evidence | Skin & Topical Longevity | Connective Tissue | 18 | 0.5% twice daily (the head-to-head RCT regimen) | One solid 12-week RCT found 0.5% bakuchiol comparable to 0.5% retinol for photoaging with less scaling and stinging, but the total evidence base is small, short and partly industry-funded. Bakuchiol is not a retinoid, and deep-wrinkle or long-term efficacy is unproven. Tolerability is its clearest advantage. |
| Berberine HCl 500 mg (AMPK) | Moderate evidence | Nutraceuticals & Cellular Energizers | AMPK / Metabolic | 18 | Human trials typically use berberine HCl 500 mg two to three times daily (about 1,000–1,500 mg/day) for 8–24 weeks, lowering… | Meta-analyses of dozens of RCTs show metformin-like reductions in fasting glucose and HbA1c (~0.6–0.9%), but the trial base is small, short and mostly Chinese, with no large rigorous confirmatory trials and no hard-outcome data. Weight-loss effects are weak despite 'nature's Ozempic' hype. GI upset is common and… |
| Glycine Powder | Moderate evidence | Nutraceuticals & Cellular Energizers | Circadian & Stress | 18 | 3 g before bedtime (sleep trials) | Sleep benefits rest on small, partly industry-affiliated trials. The aging-hallmark improvements come from small, single-site trials of GlyNAC (glycine plus N-acetylcysteine), not glycine alone, and faded after supplementation stopped; independent replication is still needed. |
| Palmitoylethanolamide (PEA) | Moderate evidence | Nutraceuticals & Cellular Energizers | Endocannabinoid / PPAR-α | 18 | — | Meta-analyses of randomized trials consistently find PEA reduces chronic pain with few side effects, but the underlying trials are small, heterogeneous and often industry-linked, so the large pooled effect sizes may shrink in bigger independent studies. Evidence supports adjunctive pain relief, not anti-aging effects. |
| Salonpas Pain Relieving Patch (Methyl Salicylate + Menthol) | Moderate evidence | Topical Pain Relief | Counter-irritant | 18 | 1 patch (methyl salicylate ~10% + menthol ~3%) over the painful area, up to 8 hours per application | Moderate evidence for short-term relief of acute muscle strain and sprains — one solid placebo-controlled patch trial plus Cochrane support — but chronic-pain data are lacking and relief is symptomatic only. Rare but real risks: skin irritation and chemical burns with occlusion or heat, and case reports of warfarin… |
| Silymarin (Milk Thistle) | Moderate evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 18 | — | Silymarin consistently lowers liver enzymes and improves metabolic markers in NAFLD and showed a fibrosis signal in the best NASH trial, but that trial missed its primary endpoint and no study proves prevention of cirrhosis or liver-related death. Plain silymarin is poorly absorbed; phytosome formulations partly… |
| Smart Humidity Monitor | Moderate evidence | Air, Water & Sleep Systems | Environmental Exposure | 18 | Target indoor relative humidity of roughly 40-60% | The link between low indoor humidity and dryness symptoms, impaired airway defense and virus transmission is well supported, and 40-60% RH is the consensus target. But interventional evidence is thin: a Cochrane review found only low-certainty benefit from humidification itself, and there are no outcome trials of… |
| Topical Tranexamic Acid Serum | Moderate evidence | Skin & Topical Longevity | Connective Tissue | 18 | 2-5% topical cream or serum, typically for 8-12 weeks | Randomized trials and meta-analyses support topical tranexamic acid for melasma, roughly comparable to hydroquinone with fewer side effects. Trials are short and heterogeneous, melasma often relapses after stopping, and benefits beyond pigmentation (general anti-aging claims) are extrapolation. |
| Blood Flow Restriction Cuffs | Moderate evidence | Recovery, Sauna & Light Therapy | Muscle & Bone | 17 | Low loads of about 20-40% of one-repetition maximum with an individualized, limb-specific cuff pressure. | Multiple meta-analyses show BFR at light loads builds muscle size comparably to heavy lifting, with somewhat smaller maximal-strength gains; in older adults it produced large strength gains and matched conventional training in one sarcopenia trial. Generally safe when supervised, but it raises exertion and… |
| Boswellia Serrata Extract | Moderate evidence | Nutraceuticals & Cellular Energizers | Inflammation (COX / LOX) | 17 | — | Trials and meta-analyses show reduced osteoarthritis pain and stiffness, but results are inconsistent - one meta-analysis found no significant overall effect once trial heterogeneity was accounted for. Many trials are small or industry-sponsored, and key boswellic acids are poorly absorbed, so the formulation matters. |
| Capzasin-HP Capsaicin 0.1% Pain Relief Cream (Pack of 3) | Moderate evidence | Topical Pain Relief | TRPV1 Nociception | 17 | 0.025–0.1% cream 3–4×/day for at least 1–2 weeks (the 8% patch is prescription-only) | A burning sensation on application is expected (about 1 extra case per 3 users in trials) and fades with regular use. Evidence is strongest for the prescription 8% patch in nerve pain; OTC creams give modest osteoarthritis relief, and a 2024 meta-analysis rates the certainty as low. Wash hands; keep away from eyes… |
| DaVinci Labs Glutathione Bright | Moderate evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 17 | Liposomal glutathione trials used 500–1,000 mg/day (Sinha 2018) and 300 mg in a 2026 crossover; by contrast, plain oral… | Oral glutathione genuinely raises body stores and lowers oxidative-stress markers in randomized trials (about 30–35% at 1,000 mg/day over 6 months), with early immune-marker signals. Clinical outcomes are thin: skin-lightening effects are modest and inconsistent, and no trial shows disease or longevity benefit.… |
| Dr. Mercola Liposomal Vitamin D3 | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 17 | The RDA is 600 IU/day (ages 1–70) and 800 IU/day (over 70); the large VITAL trial used 2,000 IU/day, and the tolerable upper… | Strong for correcting deficiency and bone health. In vitamin-D-replete adults the biggest RCTs (VITAL, DO-HEALTH) were null for cancer, cardiovascular events, fractures and mortality. Lower cancer mortality with daily dosing, fewer autoimmune diseases and preserved telomeres are secondary signals that need… |
| Hyaluronic Acid Hydrating Serum | Moderate evidence | Skin & Topical Longevity | Connective Tissue | 17 | Studied topical creams use about 0.1% HA; oral HA trials used 120 mg/day for 8-12 weeks | Controlled studies consistently show improved skin hydration and elasticity with modest fine-line reduction; effects are surface-level and reversible, not structural rejuvenation. Oral HA has placebo-controlled support but the trials are small and mostly industry-funded. Not proven for longevity. |
| Inspiratory Muscle Strength Trainer | Moderate evidence | Recovery, Sauna & Light Therapy | Cardiovascular & Vascular | 17 | 30 breaths/day at ~75% of maximal inspiratory pressure, 5-7 days/week (~5 min/day) | Blood-pressure lowering is supported by sham-controlled RCTs and two 2023 meta-analyses, one with trial-sequential confirmation. But trials are small (about 25-100 participants), short (6-12 weeks), and many come from one research group; hard outcomes like stroke and heart attack are untested. An adjunct to, not a… |
| Myo-Inositol | Moderate evidence | Nutraceuticals & Cellular Energizers | AMPK / Metabolic | 17 | 2–4 g/day | Meta-analyses support lower fasting insulin and HOMA-IR in PCOS and a possible reduction in gestational diabetes (low certainty). The review behind the 2023 international PCOS guideline calls the overall evidence limited and inconclusive, with metformin better on several outcomes. Aging or longevity outcomes are… |
| PEMF Therapy Mat | Moderate evidence | Recovery, Sauna & Light Therapy | Muscle & Bone | 17 | — | Randomized-trial meta-analyses show real short-term pain and function benefits in knee osteoarthritis, and clinical-grade devices aid fracture healing — but a review of whole-body wellness mats found the evidence insufficient, and a major insurer now judges the pain evidence inadequate. Sleep, energy and longevity… |
| Ergothioneine (L-Ergo) | Moderate evidence | Nutraceuticals & Cellular Energizers | Cardiovascular & Vascular | 16 | 25 mg three times weekly (the regimen in the 1-year cognition pilot RCT) | Human data are mostly observational: higher blood ergothioneine tracks with lower cardiovascular and all-cause mortality in large cohorts, but causality is unproven - it may partly mark a healthy, mushroom-rich diet. The one controlled cognition trial was positive but tiny (n=19). Appears safe at studied doses;… |
| TENS Pain-Relief Unit | Moderate evidence | Recovery, Sauna & Light Therapy | Neuromodulation & Nerve Signaling | 16 | — | Pooled trial data show modest, real short-term pain relief, but certainty is low-to-moderate, heterogeneity is high, and at least one condition-specific meta-analysis (chronic low back pain) is negative. Effects are transient and symptomatic; TENS is very safe but does not modify underlying disease. |
| Weighted Sleep Blanket Pro | Moderate evidence | Recovery, Sauna & Light Therapy | Circadian & Stress | 16 | About 10-12% of body weight | Trials and meta-analyses show modest improvements in insomnia severity and anxiety, mainly in people with psychiatric conditions; benefits for objectively measured sleep and for children with autism are weak or absent. Effect sizes in healthy general-population sleepers are less certain. No serious adverse events… |
| SimPure Reverse Osmosis System | Emerging evidence | Air, Water & Sleep Systems | Environmental Exposure | 33 | Same protocol as any RO system: find out what is in your water first, then decide. Replace pre-filters and the membrane on… | This filters on the same principle as reverse osmosis units costing several times more, and no trial has compared brands on any health outcome — which is the useful thing to know at this price. The removal chemistry is well documented; the health-outcome data are not, and the closest human evidence is observational,… |
| Waterdrop Undersink Reverse Osmosis | Emerging evidence | Air, Water & Sleep Systems | Environmental Exposure | 33 | Test before you buy: a certified lab test, or your utility's annual consumer confidence report, tells you whether you need this… | Reverse osmosis removes what it claims to remove; the open question is whether your water contains anything worth removing. Pull your utility's water quality report first — if it is compliant and PFAS are low, this unit is stripping contaminants that were not measurably harming you, and what you are buying is… |
| NOVOS Core All-In-One Sachets | Emerging evidence | Nutraceuticals & Cellular Energizers | NAD⁺ / Sirtuin Axis | 26 | As an all-in-one blend, there is no single studied dose; each ingredient has its own evidence and the combination as a whole is… | Human data exist only for individual ingredients, not this product: GlyNAC improved oxidative stress and physical function in older adults at doses far above what the sachets provide (and includes NAC, which the formula lacks), glucosamine's mortality link is observational, and the fisetin and alpha-ketoglutarate… |
| Fisetin Senolytic Capsules | Emerging evidence | Nutraceuticals & Cellular Energizers | Autophagy & Proteostasis | 25 | — | Nearly all senolytic evidence is preclinical, and the 2018 mouse lifespan finding was not replicated by the NIA Interventions Testing Program in 2024. Small human RCTs show anti-inflammatory effects (for example 100 mg/day for 7 weeks in cancer patients), but no published trial has shown senescent-cell clearance or… |
| NOVOS Vital Organ Support | Emerging evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 25 | A multi-ingredient blend, so there is no single human dose; effective amounts depend on each component and the specific formula.… | Evidence is ingredient-by-ingredient: modest human RCT support for nattokinase (blood pressure), lutein/zeaxanthin (eye health), and inulin (glycemia), but rutin and trehalose rest mainly on preclinical data, and trehalose showed no efficacy in the large HEALEY ALS platform trial. No trial has tested the finished… |
| Lithium Orotate (5 mg) | Emerging evidence | Nutraceuticals & Cellular Energizers | Tissue Regeneration & Repair | 22 | 5 mg elemental lithium per capsule (about 1/25th-1/40th of a psychiatric dose) | Human evidence at supplement doses is limited to brain-imaging pharmacokinetics, observational data and one small open trial; no randomized trial has tested 5 mg lithium orotate for cognition, mood or aging. The headline 2025 Nature findings came from mouse experiments, and experts caution against self-treatment… |
| Shower Dechlorination Filter | Emerging evidence | Air, Water & Sleep Systems | Environmental Exposure | 22 | — | The exposure science is solid: showering demonstrably delivers chlorine and trihalomethanes through skin and lungs, and long-term high THM exposure is associated with bladder cancer. But no study has shown that a shower filter improves any health endpoint - benefit claims rest on plausible exposure reduction, and the… |
| Luteolin Capsules | Emerging evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 21 | — | Human evidence is indication-specific and mostly for combination products, not standalone luteolin. PEA-luteolin improved post-COVID smell recovery in randomized trials, but luteolin alone was no better than placebo in a Gulf War Illness crossover trial. Oral bioavailability is poor and the… |
| Mineral Remineralization Drops | Emerging evidence | Air, Water & Sleep Systems | Cardiovascular & Vascular | 21 | — | No human trial has tested mineral drops directly — support is extrapolated from mineral-water research, where one RCT of calcium/magnesium-rich water reduced falls in older adults. Drops typically deliver small doses relative to dietary needs. A sensible way to restore what reverse-osmosis filtration strips out, not… |
| MSM with OptiMSM (1,500 mg) | Emerging evidence | Nutraceuticals & Cellular Energizers | Muscle & Bone | 21 | Knee-osteoarthritis trials used MSM about 1.5–6 g/day for 12 weeks; the most-cited trial (Kim 2006) used 3 g twice daily (6… | Weak-to-moderate: small, short, mostly industry-funded trials report modest knee-symptom benefits, and one well-run prevention trial was negative. Safety is a genuine strength (GRAS; well tolerated up to ~6 g/day). Claims beyond joint comfort, exercise recovery and skin are not well supported. |
| Anti-Noise White-Noise Sleep System | Emerging evidence | Air, Water & Sleep Systems | Cardiovascular & Vascular | 20 | — | The most rigorous systematic review graded the evidence that continuous noise improves sleep as very low quality, and recent experiments found broadband noise can itself alter sleep architecture, with earplugs outperforming masking in one traffic-noise study. It may help in genuinely noisy settings — keep volume low… |
| Tart Cherry Sleep Extract | Emerging evidence | Nutraceuticals & Cellular Energizers | Circadian & Stress | 20 | — | Positive sleep trials are small (8–20 people), short, and mostly juice-based, and recent better-powered trials using common powder doses in non-insomnia populations were null. Best case is a mild, food-level sleep aid for older adults with insomnia; formulation, dose, and baseline sleep status clearly matter. |
| Magnesium L-Threonate | Emerging evidence | Nutraceuticals & Cellular Energizers | Brain & Cognition | 19 | 1-2 g/day in trials (about 144 mg elemental magnesium per 2 g) | A few small, short, industry-funded randomized trials report cognitive and sleep benefits consistent with rodent mechanism data, but there is no independent replication and human brain-magnesium elevation has not been directly confirmed. It provides little elemental magnesium, so it is a cognitive-support candidate,… |
| Apigenin Capsules | Emerging evidence | Nutraceuticals & Cellular Energizers | NAD⁺ / Sirtuin Axis | 18 | — | The CD38/NAD⁺ longevity mechanism is demonstrated in cells and mice, not people. Human efficacy data come from chamomile-extract trials delivering far less apigenin than capsules, showing modest anxiety relief, and free apigenin is poorly absorbed in human pharmacokinetic studies. No trial has tested isolated… |
| Biofreeze Menthol Pain Relief Gel | Emerging evidence | Topical Pain Relief | TRPM8 Cooling | 18 | Apply gel to the area up to 3–4×/day as needed | Relief is mainly immediate cooling comfort, not disease-modifying; trials are small and short, mostly in acute muscle soreness. Menthol gel beat ice in one soreness trial and helped in a migraine study, but evidence for chronic joint pain is thin. NSAID-free and low-risk. |
| Pneumatic Compression Recovery Boots | Emerging evidence | Recovery, Sauna & Light Therapy | Muscle & Bone | 18 | ~20–30 min per session at ~80 mmHg in studies | Strong trial evidence supports this technology for preventing hospital blood clots and for venous and lymphatic disease, but that does not transfer to athletic recovery: a 2024 meta-analysis of 17 studies found only trivial-to-small benefits, clearest for reduced perceived soreness, with inconsistent effects on… |
| Acupressure Mat & Pillow Set | Emerging evidence | Recovery, Sauna & Light Therapy | Neuromodulation & Nerve Signaling | 16 | — | Evidence for the mat itself is very thin: the only controlled trial found daily mat use reduced subjective stress no more than simply lying down and relaxing, with no change in blood pressure, heart rate or pain thresholds. Better evidence exists for targeted acupoint acupressure (sleep, some pain), but it may not… |
| GlyNAC (Glycine + NAC) | Emerging evidence | Nutraceuticals & Cellular Energizers | Redox / Antioxidant | 16 | In the Baylor/Sekhar trials, older adults took glycine 1.33 mmol/kg and N-acetylcysteine 0.83 mmol/kg daily (~100 mg/kg of each,… | Small human trials show GlyNAC restores glutathione and improves oxidative-stress, mitochondrial and physical-function markers, but nearly all come from one research group, the largest placebo-controlled trial enrolled 24 older adults for 16 weeks, and benefits faded after stopping. The ~24% lifespan extension was… |
| Akkermansia muciniphila Probiotic | Emerging evidence | Nutraceuticals & Cellular Energizers | Gut–Immune Axis | 14 | The key trial (Depommier 2019) gave 10^10 (10 billion) cells/day of pasteurized A. muciniphila for 3 months, improving insulin… | A flagship pilot RCT and 2025-2026 follow-up trials show real but modest benefits on insulin sensitivity, weight and HbA1c, but the trial base is small, a 2026 multicenter trial missed its primary endpoint, and benefits may appear mainly in people with low baseline Akkermansia. No long-term safety or hard-outcome… |
| Topical Alpha-Lipoic Acid Cream | Emerging evidence | Skin & Topical Longevity | Connective Tissue | 14 | 5% cream (studied for 12 weeks) | One small but well-designed split-face RCT (33 women, 12 weeks) showed a 5% alpha-lipoic acid cream reduced facial roughness more than vehicle (50.8% vs 40.7% by profilometry), and one formulation study found similar anti-wrinkle effects without irritation. There are no large or long-term trials, and most commercial… |
| Phosphatidylcholine (PC) Complex | Preliminary | Nutraceuticals & Cellular Energizers | Mitochondrial Energy | 25 | Adequate Intake for choline is 550 mg/day (men) and 425 mg/day (women); supplements supply choline as phosphatidylcholine, which… | Evidence is claim-specific and mostly discouraging: small ulcerative-colitis trials looked promising but both large 2024 phase 3 trials failed, and Cochrane found no clear benefit of lecithin for dementia. A 2025 sarcopenia-cognition signal is hypothesis-generating only, and gut conversion of PC to TMAO is an… |
| Copper Tripeptide (GHK-Cu) Serum | Preliminary | Skin & Topical Longevity | Connective Tissue | 21 | — | Decades of laboratory and animal data show wound-healing and collagen-stimulating effects, but rigorous human trials for skin aging are essentially absent — the best controlled study found no objective benefit, only higher patient satisfaction. Skin penetration is a known limitation that newer liposomal formulations… |
| Allergen Alert Mini Food Lab | Preliminary | Biometric Wearables & Sensors | Gut–Immune Axis | 18 | There is no validated protocol for this device. If you use one at all, use it as an extra check on top of asking the kitchen,… | There is no peer-reviewed validation of this device — not a small study, not a flawed one, none. It launched at CES in January 2026, has no PubMed record, and publishes no sensitivity, specificity or limit of detection, so nothing here is graded on its own data. What can be graded is the category, and that history is… |
| Saliva Cortisol Stress Test | Preliminary | Diagnostics & Epigenetic Tests | Biomarkers & Biological Age | 17 | — | Salivary cortisol is a legitimate assay - late-night salivary cortisol is one of the recommended first-line tests for suspected Cushing syndrome, and its diagnostic accuracy has been characterised across 139 studies - but that is a specific endocrine question, asked by a clinician about a patient with reasons to… |
| Apple Watch Series 11 | Measurement tool | Biometric Wearables & Sensors | Circadian & Stress | 104 | If the cardiac features are why you are buying it, turn on irregular rhythm notifications and AFib History and wear it… | This is the most rigorously evaluated device on the list, and the regulatory picture is real: the ECG app, irregular rhythm notifications, AFib History, sleep apnea notifications and hypertension notifications are all FDA-cleared. Cleared means the feature performs as described, not that using it makes you healthier… |
| Fitbit Inspire 3 | Measurement tool | Biometric Wearables & Sensors | Circadian & Stress | 104 | Wear it every day and use one number: steps. Aim for a personal increase of 1,000-2,000 steps a day over where you currently… | This is the honest value on the list, and the reason is unflattering to everything above it: for the single output with strong outcome evidence behind it - the step count - a cheap tracker performs about as well as a watch costing eight times more. The step evidence itself is genuinely strong: pooled across 15… |
| Fitbit Sense 2 | Measurement tool | Biometric Wearables & Sensors | Circadian & Stress | 104 | Leave irregular rhythm notifications on and wear it overnight for the sleep and resting heart rate trend. If you get a… | Two features here are genuinely FDA-cleared: the ECG app, cleared in 2020, and the photoplethysmography-based irregular rhythm notifications, cleared in 2022. The Fitbit Heart Study is the honest reading of the second - of 455,699 participants only 1% ever received a detection, and among those who wore a confirmatory… |
| Garmin Forerunner 265 | Measurement tool | Biometric Wearables & Sensors | Circadian & Stress | 104 | Use it for pace, distance and steps; pair a chest strap for interval and threshold work, because wrist optical heart rate lags… | Garmin's optical heart rate is among the better performers at rest and steady state and its GPS-derived pace and distance hold up, but no brand measures energy expenditure accurately, and a Garmin watch running the same submaximal-run algorithm underestimated laboratory gas-analysis VO2max by about 4.7 mL/kg/min,… |
| Garmin Vivoactive 6 | Measurement tool | Biometric Wearables & Sensors | Circadian & Stress | 104 | Use it for steps, pace and everyday heart rate; add a chest strap if you train by heart-rate zones. Read the sleep score as a… | This is the same measurement platform as the more expensive Garmins with fewer running features, and it inherits the same profile: steps are accurate enough to act on, heart rate is good at rest and steady state and degrades with wrist motion, and energy expenditure is not accurate in any consumer device from any… |
| Oura Ring Gen 4 | Measurement tool | Biometric Wearables & Sensors | Circadian & Stress | 104 | Wear it nightly for at least two weeks before reading anything into a number; single nights are noise. The defensible outputs… | For duration and cardiac metrics this is the best-validated device on this list: against an ECG reference across 536 nights the Gen 4 gave nocturnal resting heart rate within about 2% and HRV within about 6%, the best of five wearables tested, and against multi-night polysomnography the Gen 3 did not differ… |
| Polar Vantage Watch | Measurement tool | Biometric Wearables & Sensors | Circadian & Stress | 104 | Wear it daily and treat the step count as the one output with real outcome evidence behind it. Read sleep stages, Nightly… | Polar's step counts and sleep duration track research instruments closely enough to be useful, but the systematic review of wrist-worn Polar devices concluded their accuracy remains unclear because the individual studies conflict, and energy-expenditure error is large in all of them. Against polysomnography in… |
| WHOOP Band 5.0 | Measurement tool | Biometric Wearables & Sensors | Circadian & Stress | 104 | Wear it continuously and read Recovery as a rolling trend across weeks. If you are going to act on HRV, act on the direction of… | WHOOP is good at the thing it does not advertise and weaker at the thing it does. Against polysomnography it got total sleep time almost exactly right - an 8-minute non-significant overestimate, and in a later systematic review the smallest total-sleep-time disagreement of the devices compared - but its specificity… |
| Withings Body Scan Scale | Measurement tool | Biometric Wearables & Sensors | Biomarkers & Biological Age | 23 | Weigh at the same time each morning, after voiding and before eating, and read the trend line over weeks rather than any single… | The FDA clearance on this scale is narrow and specific: it covers detection of atrial fibrillation from the 6-lead ECG, and nothing else. The bioimpedance body composition is the part most people buy it for, and it is the part that does not hold up at an individual level: against DXA, bioimpedance underestimates… |
| GGT Liver-Health Test | Measurement tool | Diagnostics & Epigenetic Tests | Biomarkers & Biological Age | 22 | Not a tracking test. Reasonable once if you have a concrete reason - regular alcohol intake you want an objective read on, a… | GGT is a real risk marker, not a curiosity - pooled across 19 cohorts and more than 9 million people, those in the top third had roughly 1.6 times the all-cause mortality of the bottom third. It is also about as non-specific as a blood test gets - it rises with alcohol, with a long list of ordinary medications, with… |
| Omega-3 Index Test | Measurement tool | Diagnostics & Epigenetic Tests | Biomarkers & Biological Age | 22 | Once to find your baseline, then again about 4 months after changing oily fish intake or starting a supplement - red cell fatty… | This is the one test on the list where the analyte and the method were developed together and both hold up. Pooled across 17 prospective cohorts, higher blood omega-3 levels tracked lower total and cause-specific mortality, the Framingham data point the same way, and the index adds predictive information on top of… |
| Wearable Pulse Oximeter | Measurement tool | Air, Water & Sleep Systems | Biomarkers & Biological Age | 22 | If you use one, sit still, warm your hands, remove nail polish, and take the reading at rest - cold fingers and motion are the… | The accuracy problem with pulse oximetry is a safety problem rather than a nuance. These devices read high in people with darker skin: pooled bias is about 1.1% for high skin pigmentation and 1.5% in people described as Black or African American, and in a meta-analysis of 23 studies the accuracy root-mean-square… |
| FreeStyle Libre CGM | Measurement tool | Biometric Wearables & Sensors | AMPK / Metabolic | 20 | Treat it as a two-week experiment, not a permanent feed. Test specific questions — how your usual breakfast compares with a… | Two questions matter for a CGM worn without diabetes, and both answers are uncomfortable. On accuracy: in healthy adolescents the Libre's mean absolute relative difference against fingerstick plasma glucose was 13.1%, with only 68% of paired readings meeting the ISO 15197:2013 criterion, and in children without… |
| hs-CRP Inflammation Test | Measurement tool | Diagnostics & Epigenetic Tests | Biomarkers & Biological Age | 19 | Only when you are well. Check it twice, a couple of weeks apart, and take the lower value - a single high reading is far more… | hs-CRP has earned its place: it separated risk independently of LDL cholesterol in the classic NEJM prediction work, and in 30-year follow-up of the Women's Health Study it was still carrying predictive information decades after a single measurement. The measurement travels better than most on this list - CRP has… |
| Lp(a) Mail-In Test | Measurement tool | Diagnostics & Epigenetic Tests | Biomarkers & Biological Age | 19 | Once in adult life. Lp(a) is set by the LPA gene you were born with and moves very little afterwards, so one good result is the… | The analyte is about as solid as anything on this site: LPA gene variants that raise Lp(a) track coronary disease in a dose-dependent way, the European Atherosclerosis Society treats a raised level as an independent causal risk factor, and in the 30-year follow-up of the Women's Health Study a single baseline Lp(a)… |
| ApoB Home Test Kit | Measurement tool | Diagnostics & Epigenetic Tests | Biomarkers & Biological Age | 18 | Once to find out where you stand, then repeat about 8-12 weeks after any deliberate change - a statin, a real diet change,… | ApoB counts atherogenic particles rather than the cholesterol inside them, and where the two disagree the particle count is the better guide to risk - that part is well supported and is why several lipid guidelines now list it as a preferred target. Whether a mailed finger-stick delivers that number reliably is a… |
| Cystatin C / eGFR Kidney Test | Measurement tool | Diagnostics & Epigenetic Tests | Biomarkers & Biological Age | 18 | Not a routine self-monitoring test. Reasonable once if you have a specific reason to think a creatinine-based eGFR is misleading… | Cystatin C genuinely outperforms creatinine alone. It is less dependent on muscle mass, the combined creatinine-cystatin C equation estimates GFR more accurately than either marker by itself, and where the two estimates disagree the cystatin C-based number is the one that tracks mortality and kidney outcomes - a… |
| Ferritin / Iron-Status Test | Measurement tool | Diagnostics & Epigenetic Tests | Biomarkers & Biological Age | 18 | Reasonable once if you have a specific reason - heavy periods, a plant-based diet, blood donation, unexplained fatigue - and… | Ferritin is the standard first-line marker of iron stores and a genuinely low value is informative. The trap is that ferritin is also an acute-phase reactant, so it rises with infection, inflammation, obesity and liver disease - which means a normal or even high ferritin does not rule out iron deficiency in anyone… |
| Fasting Insulin / HOMA-IR Kit | Measurement tool | Diagnostics & Epigenetic Tests | Biomarkers & Biological Age | 16 | Fasting 10-12 hours, and only ever compared against your own previous result from the same laboratory. Twice a year at most.… | HOMA-IR is a reasonable idea with a real problem underneath it. The formula itself has been in use since 1985 and correlates acceptably with clamp measures at a population level, but it is built on a fasting insulin value, and insulin has no reference measurement procedure - when 12 commercial assays from 9… |
| Grip-Strength Dynamometer | Measurement tool | Diagnostics & Epigenetic Tests | Cardiovascular & Vascular | 16 | Three squeezes per hand, seated, elbow at 90 degrees, best value recorded - and the same chair, same arm position, same time of… | Grip strength is one of the most durable prognostic markers in epidemiology: in PURE across 17 countries and in half a million UK Biobank participants, lower grip tracked all-cause and cardiovascular mortality, and it did so after adjustment and across very different populations. This specific device also clears the… |
| SYB Clear Blue Light Glasses | Tested — did not work | Air, Water & Sleep Systems | Circadian & Stress | 22 | No protocol, because no wearing schedule has been shown to produce a benefit. If the goal is screen comfort, the treatable… | These have been tested properly and they did not work. That distinction matters: this is not thin evidence, it is adequate evidence pointing at nothing, which is why it is graded at the bottom rather than as something promising. The 2023 Cochrane review pooled 17 randomized trials and concluded that blue-light… |
How each grade was reached, and what the dataset does not claim.
All 64 fields across both tables, defined.
The same catalogue written as prose.
The citation graph behind these grades.
The interactive version of the grading rubric.